HEREDITARY HEMORRHAGIC TELANGIECTASIA
Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA trials appear
Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to stop nosebleeds in rare blood vessel disorder
Disease control Not yet recruitingThis study tests an experimental drug called ATV-1601 in people with moderate to severe HHT, a condition that causes frequent nosebleeds and anemia. The trial has two parts: first, participants receive either the drug or a placebo to check safety and effectiveness; then, all elig…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Phase: PHASE1, PHASE2 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New antibody aims to tame rare bleeding disorder
Disease control Not yet recruitingThis early-phase trial tests an experimental antibody called DIAG723 in 93 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The study will check if the drug is safe and how the body processes it, with…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Phase: PHASE1, PHASE2 • Sponsor: Diagonal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC